Navigation Links
Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
Date:7/30/2013

KING OF PRUSSIA, Pa., July 30, 2013 /PRNewswire/ -- Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today the publication of new findings related to the mechanism of action of its Angiotensin II Type 1 Receptor (AT1R) biased ligands. The publication describes work led by R. John Solaro PhD, Distinguished University Professor and Head of the Department of Physiology and Biophysics at the University of Illinois at Chicago, performed in collaboration with Trevena scientists.  The studies evaluated the molecular mechanisms of action for TRV120023, a molecule closely related to Trevena's clinical stage asset, TRV027, which is in Phase 2 testing for the treatment of acute heart failure. TRV027 is being developed by Trevena under a recently announced collaborative licensing option agreement with Forest Laboratories Inc. (NYSE: FRX).

The article, entitled "The Beta-arrestin-Biased Ligand TRV120023 Inhibits Angiotensin II-Induced Cardiac Hypertrophy While Preserving Enhanced Myofilament Response to Calcium", was published online, ahead of print, July 19, 2013, in the American Journal of Physiology - Heart and Circulatory Physiology.

Work in Dr. Solaro's laboratory showed that TRV120023 blocked cardiac hypertrophy in rats, while stimulating biochemical pathways linked to increased cardiac contractility.  TRV120023 increased the sensitivity of cardiac myofilaments to calcium, suggesting that TRV120023 and molecules like it, such as TRV027, can increase cardiac contractile force ("inotropy") through a mechanism distinct from classic inotropes, which are associated with cardiac arrhythmia and increased mortality. Dr Solaro said of the published work, "these experiments suggest that Trevena's biased ligands regulate the heart's contractile machinery through a novel mechanism which may simultaneously block cardiac dysfunction while promoting cardiac contractility"

Michael Lark Ph.D., Trevena's Chief Scientific Officer, commented that "these findings further support the hypothesis that beta-arrestin biased ligands like TRV120023 and TRV027 may offer unique benefits in treating cardiovascular disease." 

About Acute Heart Failure

The American Heart Association estimated that acute heart failure (AHF) hospitalization costs the U.S. healthcare system more than $20 billion each year in direct spending. AHF is already the leading reason for hospitalization of individuals over 65 years old in the United States, with over 1 million hospital admissions per year. AHF is also the most costly diagnosis for Medicare in the nation. Despite the significance of this problem, current therapies are not producing meaningful improvements in patient outcomes. AHF incidence is increasing globally, and both heart failure mortality and hospital re-admission following an AHF event remain extremely high.

About Trevena

Trevena, Inc. is dedicated to discovering and developing the next generation of GPCR targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. In addition to TRV027, Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand, TRV130, for post-operative pain, and discovery-stage programs for chronic pain and Parkinson's disease.

For more information, please contact:
Ros Deegan, VP Business Development, Trevena Inc., 610-354-8840 x225 (Corporate)
Kimberly Minarovich, Christensen, 917-533-3268 (Media)


'/>"/>
SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
2. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
3. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
4. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
5. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
6. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
7. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
8. Cardiac Science to Supply Q-Tel Data to AACVPR Cardiac Rehabilitation Registry
9. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
10. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
11. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):